Drug or treatment

Adebrelimab clinical trials

• 90Clinical trials
• 1New in 30 days
• 1Country

Newest trials

All recruiting trials (90)

• Propranolol with Adebrelimab and Platinum Chemotherapy in Small Cell Lung Cancer

  This early-phase trial tests whether adding propranolol to adebrelimab plus platinum chemotherapy is safe and may help treat small cell lung cancer in adults.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan and 3 other locations · NCT07886047

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

• Shrinkage-free combo in LS-SCLC: SHR-7787 plus SHR-1316

  This trial tests whether the combo of SHR-7787 and SHR-1316 can help adults with unresectable limited-stage small cell lung cancer after prior platinum-based chemo and radiation.

  Recruiting Phase 2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Jinan, Shandong · NCT07798947

• Neoadjuvant therapy with adebrelimab, famitinib, and chemotherapy for resectable ESCC

  This study tests a combination of adebrelimab, famitinib, and chemotherapy before surgery in people with resectable locally advanced esophageal squamous cell carcinoma to see if it can lead to a complete tumor disappearance at the time of surgery.

  Recruiting Phase 2 First Affiliated Hospital Xi'an Jiaotong University · Xi'an, Shannxi · NCT07796113

• A combination therapy for advanced second-line gastric cancer using apatinib with albumin-bound paclitaxel, with or without adebrelimab

  This study tests whether adding adebrelimab to a regimen of apatinib and albumin-bound paclitaxel helps patients with advanced gastric or gastroesophageal junction cancer who did not respond to first-line therapy.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT07770113

• Short-course radiotherapy with Adebrelimab and platinum chemo before surgery for locally advanced cervical cancer

  This trial tests a short course of radiotherapy combined with Adebrelimab and platinum chemotherapy to shrink locally advanced cervical cancer before surgery.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07731828

• Trastuzumab Rezetecan with Adebrelimab and Lenvatinib for advanced HER2-positive/low-expression biliary tract cancer

  This study tests a triple therapy to see if it helps people with advanced biliary tract cancer that is HER2-positive or has low HER2 expression after at least one prior treatment.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07704177

• Combination therapy for residual triple-negative breast cancer after neoadjuvant treatment

  This Phase 3 trial tests whether Trastuzumab Rezetecan plus Adebrelimab works better than the investigator’s choice in people with residual invasive triple-negative breast cancer after prior treatment.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07679360

• First-line treatment with Trastuzumab Rezetecan, Adebrelimab, and Lenvatinib for advanced HER2-positive or HER2-low biliary tract cancer

  This phase II trial tests whether a combination of Trastuzumab Rezetecan, Adebrelimab, and Lenvatinib can help people with advanced HER2-positive or HER2-low biliary tract cancer respond to treatment as a first line therapy.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing · NCT07670273

• First-line combination therapy with adebrelimab, gemcitabine, and nab-paclitaxel for biliary tract cancers

  A multicenter, single-arm study tests whether a PD-1 blocker (adebrelimab) plus chemotherapy (gemcitabine and nab-paclitaxel) is safe and effective as first-line treatment for biliary tract cancers that can’t be surgically removed.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07668453

• Radiotherapy with chemotherapy plus adebrelimab and bevacizumab for TNBC with brain metastases

  This phase II study tests a combination of radiotherapy, cisplatin or carboplatin, adebrelimab, and bevacizumab in adults with triple-negative breast cancer that has spread to the brain.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07638852

• Adebrelimab plus chemotherapy before surgery for borderline-resectable esophageal squamous cell carcinoma

  This trial tests whether adding adebrelimab to chemotherapy given before surgery can shrink borderline-resectable ESCC enough to allow curative tumor removal.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07638436

• Neoadjuvant radiotherapy with NALIRIFOX and Adebrelimab in locally advanced rectal cancer

  This trial tests whether adding radiotherapy and a PD-1 blocker called Adebrelimab to a chemotherapy regimen (NALIRIFOX) before surgery helps people with locally advanced, pMMR/MSS rectal cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07622771

• Adebrelimab with neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma

  This study tests whether giving adebrelimab with paclitaxel, carboplatin, and short-course radiotherapy before surgery helps ESCC patients.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07595770

• NALIRIFOX plus adebrelimab and PULSAR as first-line treatment for advanced pancreatic cancer

  This study tests a combination of NALIRIFOX chemotherapy with adebrelimab and PULSAR as first-line therapy for locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma to see if it is safe and shows initial signs of effectiveness.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07595172

• Low-dose chest radiation followed by adebrelimab with chemotherapy, then maintenance therapy for extensive-stage small cell lung cancer

  This trial tests whether giving a low, focused dose of chest radiotherapy together with chemotherapy and the drug adebrelimab helps people with extensive-stage small cell lung cancer, with maintenance adebrelimab afterward.

  Recruiting Phase 2 Jiangmen Central Hospital · Jiangmen, Guangdong · NCT07583550

• Alternating liver-artery and IV chemotherapy with optional adebrelimab and apatinib for unresectable biliary tract cancer

  This study will test whether alternating hepatic arterial infusion chemotherapy and standard IV gemcitabine–cisplatin, with or without the immunotherapy adebrelimab and the targeted drug apatinib, helps people with unresectable biliary tract cancer shrink tumors and live longer.

  Recruiting Phase 2 Air Force Military Medical University, China · Xi'an, Shaanxi · NCT07569679

• Adebrelimab consolidation after chemoradiotherapy for limited-stage small-cell lung cancer

  This study tests whether adding adebrelimab after chemoradiotherapy helps patients with untreated limited-stage small-cell lung cancer see better outcomes.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan and 1 other locations · NCT07559786

• Perioperative adebrelimab with S-1 and oxaliplatin for locally advanced gastric or gastroesophageal junction cancer

  This trial tests whether adding the immunotherapy adebrelimab to standard chemotherapy (S-1 and oxaliplatin) given around surgery can help people with locally advanced stomach or gastroesophageal junction cancer stay free of cancer events longer.

  Recruiting Phase 3 Shanghai Shengdi Pharmaceutical Co., Ltd · Beijing, Beijing Municipality · NCT07522151

• Adebrelimab plus SHR-8068 with chemoradiotherapy as perioperative care for resectable locally advanced rectal cancer.

  This trial will test whether adding two immunotherapy drugs (adebrelimab and SHR-8068) to chemoradiotherapy around the time of surgery helps people with resectable locally advanced rectal cancer.

  Recruiting at 2 sites Phase 2/3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Wuhan, Hubei and 1 other locations · NCT07454720

• Neoadjuvant adebrelimab plus chemotherapy for esophageal squamous cell carcinoma

  This study will test whether giving adebrelimab together with chemotherapy before surgery helps people with locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 2 The Affiliated Hospital of Putian University · Putian, Fujian · NCT07437898

• Adebrelimab for advanced small cell lung cancer in routine care

  This project will try adebrelimab, a PD-L1 blocker, in adults with extensive-stage small cell lung cancer to see how safe it is and how well it controls the disease in routine clinical care.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07434518

• Adebrelimab plus platinum chemotherapy before surgery for operable esophageal squamous cell carcinoma

  This trial will try giving adebrelimab with platinum-based chemotherapy before surgery in people with locally advanced, resectable esophageal squamous cell carcinoma to see if it increases complete tumor disappearance and is safe.

  Recruiting The Second Hospital of Shandong University · Jinan · NCT07430579

• SHR-A2102 plus adebrelimab versus platinum-based chemotherapy for advanced urothelial carcinoma

  This test compares SHR-A2102 combined with adebrelimab to gemcitabine with cisplatin or carboplatin in people with previously untreated locally advanced or metastatic urothelial carcinoma.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07393542

• Adebrelimab plus gemcitabine, cisplatin, and simvastatin for advanced biliary tract cancer

  This trial tests whether adding adebrelimab and simvastatin to standard gemcitabine–cisplatin chemotherapy helps people with advanced biliary tract cancer.

  Recruiting Phase 1/2 Tongji Hospital · Wuhan, Hubei · NCT07392541

• Adebrelimab and apatinib with SOX chemotherapy to make advanced stomach or GE junction cancer operable

  This treatment tests whether adding adebrelimab and apatinib to SOX chemotherapy can shrink advanced stomach or gastroesophageal junction adenocarcinomas so more people can have surgery.

  Recruiting Phase 2 Beijing Friendship Hospital · Beijing, Beijing Municipality · NCT07353684

• Adebrelimab with famitinib and irinotecan for advanced stomach cancer after first-line treatment stops working

  This trial will try whether adding the immune drug adebrelimab and the targeted drug famitinib to irinotecan helps people with advanced stomach or gastroesophageal junction cancer whose first-line treatment has stopped working.

  Recruiting Phase 2 Shandong Tumor Hospital · Jinan, Shandong · NCT07309185

• Trastuzumab Rezetecan with or without Adebrelimab for HER2-expressing advanced urothelial cancer

  This study will test whether Trastuzumab Rezetecan alone or combined with the immunotherapy Adebrelimab helps people with HER2-expressing locally advanced or metastatic urothelial cancer.

  Recruiting at 3 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT07241793

• SHR-8068 with adebrelimab and chemotherapy versus tislelizumab with chemotherapy for first-line advanced or metastatic non-small cell lung cancer

  This trial will test whether SHR-8068 plus adebrelimab with platinum chemotherapy works better than tislelizumab with platinum chemotherapy as first treatment for adults with newly diagnosed advanced or metastatic non-small cell lung cancer.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Jinan, Shandong · NCT07170995

• Adebrelimab plus concurrent chemoradiotherapy versus placebo for locally advanced cervical cancer

  This trial will test whether adding adebrelimab to standard concurrent chemoradiotherapy helps people with locally advanced cervical cancer live longer without their cancer getting worse.

  Recruiting Phase 3 Shanghai Shengdi Pharmaceutical Co., Ltd · Shanghai, Shanghai Municipality · NCT07168200

• Adebrelimab plus etoposide capsules as maintenance therapy for extensive-stage small cell lung cancer

  This phase 2 trial will test whether adebrelimab combined with etoposide capsules as maintenance therapy helps people with extensive-stage small cell lung cancer who had no progression after initial platinum-based chemotherapy with adebrelimab.

  Recruiting Phase 2 Tang-Du Hospital · Xi'an, Shannxi · NCT07141264

• Adebrelimab with apatinib plus gemcitabine–cisplatin for initially unresectable biliary tract cancer

  This trial tests whether adding the immunotherapy adebrelimab and the targeted drug apatinib to standard chemotherapy helps people with newly diagnosed, unresectable biliary tract cancer.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT07135544

• HRS-4642 with gemcitabine, albumin-bound paclitaxel and adebrelimab before and after surgery for pancreatic cancer

  This trial tests whether adding HRS-4642 to chemotherapy (gemcitabine plus albumin-bound paclitaxel) and adebrelimab helps people with resectable or borderline resectable pancreatic cancer when given before and after surgery.

  Recruiting Phase 2 Ruijin Hospital · Shanghai · NCT07131514

• Adebrelimab with SHR-A1811/SHR-A1904 plus chemotherapy or with SHR-8068 for gastric and gastroesophageal-junction cancer

  This trial tests whether adding Adebrelimab to SHR-A1811 or SHR-A1904 plus chemotherapy, or combining Adebrelimab with SHR-8068, improves outcomes for adults newly diagnosed with gastric or gastroesophageal-junction cancer who have not yet received treatment.

  Recruiting at 2 sites Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shijiazhuang, Hebei and 1 other locations · NCT07110571

• Nimotuzumab plus Adebrelimab with chemotherapy for cisplatin‑ineligible head and neck cancer

  This trial will try combining nimotuzumab and adebrelimab with chemotherapy to see if the regimen is safe and helps people with recurrent or metastatic head and neck squamous cell carcinoma who cannot receive high‑dose cisplatin.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT07105592

• SHR-A2102 with adebrelimab, with or without other anti-cancer drugs, for recurrent or metastatic head and neck squamous cell carcinoma

  This tests whether SHR-A2102 combined with adebrelimab, with or without other anti-cancer therapies, is safe and helps adults with recurrent or metastatic head and neck squamous cell carcinoma.

  Recruiting at 2 sites Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Chongqing, Chongqing Municipality and 1 other locations · NCT07059221

• Combining Adebrelimab with Chemoradiotherapy and Surgery for Gastric Cancer

  This study is testing if adding a new immunotherapy drug called Adebrelimab to standard treatments for stomach cancer can help patients with advanced cases do better and have a better chance of recovery.

  Recruiting Phase 2 Jiangsu Cancer Institute & Hospital · Nanjing, Province · NCT06985602

• Combining Apatinib, Adebrelimab, and Chemotherapy for Advanced Intrahepatic Cholangiocarcinoma

  This study is testing a new treatment that combines two medications with chemotherapy to see if it can help people with advanced liver cancer respond better than with standard chemotherapy alone.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06925516

• Adebrelimab with chemotherapy with or without radiotherapy as neoadjuvant treatment for HER2-negative locally advanced breast cancer

  This study tests whether adding Adebrelimab to standard chemotherapy, with or without radiotherapy, can improve outcomes for women with HER2-negative locally advanced breast cancer before surgery.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT06908668

• SHR-A2102 plus adebrelimab for muscle-invasive bladder cancer

  This study tests whether injections of SHR-A2102 combined with adebrelimab help adults with non-metastatic muscle-invasive bladder cancer and in phase III compares the combo to standard gemcitabine plus cisplatin chemotherapy.

  Recruiting Phase 2/3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shanghai, Shanghai Municipality · NCT06879145

• Perioperative adebrelimab plus chemotherapy for resectable locally advanced esophageal squamous carcinoma

  We will test if giving adebrelimab with preoperative nab‑paclitaxel and cisplatin, followed by postoperative adebrelimab, helps people with resectable locally advanced esophageal squamous carcinoma.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT06869213

• New treatment for advanced small cell lung cancer

  This study is testing a new combination of treatments for people with advanced small cell lung cancer who haven't had success with their first round of chemotherapy.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT06853678

• Combination treatment for advanced gastric and gastro-esophageal junction cancer

  This study is testing a new combination treatment for people with advanced stomach cancer to see if it helps them before and after surgery.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT06808971

• Combining pegylated liposomal doxorubicin and adebrelimab with or without mirabegron for relapsed ovarian cancer

  This study is testing a new treatment combination for adults with relapsed ovarian cancer to see if adding mirabegron to pegylated liposomal doxorubicin and adebrelimab makes it work better.

  Recruiting Phase 2/3 Obstetrics & Gynecology Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT06791460

• Combining Adebrelimab with chemotherapy for advanced gastric cancer

  This study is testing if combining a new drug called Adebrelimab with chemotherapy can help people with advanced stomach cancer feel better and live longer.

  Recruiting Phase 1/2 Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center · Shenzhen, Guangdong · NCT06776770

• Combining adebrelimab with chemotherapy for lung cancer treatment

  This study is testing if adding adebrelimab to chemotherapy helps patients with early-stage lung cancer feel better and have better treatment outcomes before surgery.

  Recruiting Phase 2 The First Affiliated Hospital of Guangzhou Medical University · Guangzhou · NCT06775275

• Adebelizumab with chemotherapy given with radiotherapy at the same time versus after radiotherapy for extensive-stage small cell lung cancer

  This study tests whether adding adebelizumab to chemo and radiotherapy works better when given at the same time as radiotherapy compared to after radiotherapy in adults with extensive-stage SCLC.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT06768307

• Combining irinotecan liposome or etoposide with adebrelimab and carboplatin for extensive stage small cell lung cancer

  This study is testing two different treatment combinations to see if they can help people with extensive stage small cell lung cancer live longer and feel better.

  Recruiting Phase 2 Guangzhou Institute of Respiratory Disease · Guangzhou, Guangzhou · NCT06739928

• Combination treatment for advanced liver cancer

  This study is testing a new combination of treatments for people with advanced liver cancer to see if it can help them respond better and live longer.

  Recruiting at 3 sites Phase 2 Sun Yat-sen University · Lanzhou, Gansu and 2 other locations · NCT06737913

• Comparing 2 vs 4 cycles of Adebrelimab for esophageal cancer treatment

  This study is testing whether getting 2 or 4 cycles of a new treatment combined with chemotherapy can help people with advanced esophageal cancer respond better before surgery.

  Recruiting Phase 2 Tang-Du Hospital · Xi'an, Shannxi · NCT06663059

• Treatment of advanced biliary tract tumors with HRS-4642 alone or with adebrelimab

  This study is testing if a new treatment called HRS-4642, alone or with another drug called adebrelimab, can help people with advanced biliary tract cancer who haven't had success with other treatments.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT06620848

• Treatment for advanced liver cancer using new drug combinations

  This study is testing whether a new combination of drugs can help people with advanced liver cancer live longer and feel better compared to another treatment option.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Hefei, Anhui · NCT06618664

• Combining Fruquintinib, Adebrelimab, and Radiotherapy for Advanced Colorectal Cancer

  This study is testing a new treatment that combines Fruquintinib, Adebrelimab, and radiotherapy to see if it can help people with advanced colorectal cancer who haven't responded to other treatments.

  Recruiting Ningbo Medical Center Lihuili Hospital · Ningbo, Zhejiang · NCT06613113

• Adebrelimab plus chemotherapy with concurrent low-dose radiotherapy for extensive-stage small cell lung cancer

  This trial tests whether adding the immunotherapy adebrelimab to standard chemotherapy together with low-dose radiotherapy helps adults with extensive-stage small cell lung cancer live longer or respond better to treatment.

  Recruiting Phase 2 Sichuan University · Sichuan · NCT06610734

• Combining Adebrelimab with Capecitabine for High-Risk Cholangiocarcinoma After Surgery

  This study is testing if combining a new immunotherapy drug with a chemotherapy drug can help prevent cancer from coming back in adults with high-risk cholangiocarcinoma after surgery.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu and 3 other locations · NCT06607276

• Adebrelimab and chidamide with gemcitabine plus S-1 for advanced pancreatic cancer

  This study will test whether adding the immunotherapy adebrelimab and the oral drug chidamide to standard chemotherapy (gemcitabine plus S-1) helps people with unresectable locally advanced or metastatic pancreatic cancer respond better or live longer.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu · NCT06584227

• Combining adebrelimab with chemotherapy and SBRT for treating early-stage small cell lung cancer

  This study is testing if adding the immunotherapy drug adebrelimab to chemotherapy and radiation can help people with early-stage small cell lung cancer before they have surgery.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06562920

• Combining SHR-A2102 and Adebrelimab for Advanced Lung Cancer

  This study is testing a new combination of two drugs, SHR-A2102 and Adebrelimab, to see if they can help people with advanced lung cancer feel better and improve their treatment outcomes.

  Recruiting Phase 1/2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT06512051

• Treatment for advanced esophageal squamous cell carcinoma using adebrelimab and chemotherapy

  This study is testing if a new immunotherapy called adebrelimab, with or without chemotherapy, can help people with advanced esophageal cancer feel better and improve their treatment outcomes.

  Recruiting Phase 2 Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT06510660

• Combination of adebrelimab and XELOX for treating advanced gastric cancer before surgery

  This study is testing if combining a new immune treatment with chemotherapy can help people with advanced stomach cancer live longer and have fewer recurrences after surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT06506292

• Using Adebrelimab with chemotherapy for early-stage small cell lung cancer

  This study is testing if adding Adebrelimab to chemotherapy helps people with early-stage small cell lung cancer do better before surgery compared to just chemotherapy alone.

  Recruiting Phase 2 Tang-Du Hospital · Xi'an, Shannxi · NCT06485544

• Combining Adebrelimab, Apatinib Mesylate, and Chemotherapy for Treating Limited-stage Small Cell Lung Cancer

  This study is testing a new combination of a drug called adebrelimab, another drug called apatinib mesylate, and chemotherapy to see if it helps people with newly diagnosed limited-stage small cell lung cancer.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06483282

• Combining immunotherapy with chemotherapy for esophagogastric junction cancer treatment

  This study is testing if combining a new immunotherapy drug with standard chemotherapy can help people with operable esophagogastric junction cancer feel better and improve their treatment outcomes.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06482788

• Using Adebrelimab and Apatinib for treating advanced small cell lung cancer

  This study is testing if a combination of Adebrelimab and Apatinib can help people with advanced small cell lung cancer live longer and feel better after their initial treatment.

  Recruiting China Medical University, China · Shenyang, Liaoning and 1 other locations · NCT06480864

• Combining Adebrelimab, Recaticimab, and Chemotherapy for Lung Cancer Treatment

  This study is testing if a new combination of two immune treatments and chemotherapy can improve outcomes for patients with operable stage II-III lung cancer.

  Recruiting Phase 2 Beijing Chest Hospital, Capital Medical University · Beijing, Beijing Municipality · NCT06467617

• Comparing GP chemotherapy with and without adebrelimab for nasopharyngeal carcinoma

  This study is testing if adding a new immune treatment called adebrelimab to standard chemotherapy can help people with advanced nasopharyngeal cancer respond better to treatment and live longer.

  Recruiting Phase 2 Sun Yat-sen University · Foshan, Guangdong and 11 other locations · NCT06455410

• Combining Adebrelimab and Apatinib for Liver Cancer Patients at High Risk of Recurrence

  This study is testing if combining two medications, Adebrelimab and Apatinib, can help liver cancer patients who are at high risk of their cancer coming back after surgery.

  Recruiting Phase 2 Qilu Hospital of Shandong University · Jinan, Shandong · NCT06454578

• Combination treatment for metastatic pancreatic cancer

  This study is testing a new combination of treatments for people with metastatic pancreatic cancer to see if it can help their immune system fight the cancer better.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT06454448

• ADCs plus adebrelimab in HER2-negative advanced breast cancer

  This study tests three antibody-drug conjugates (SHR-A1811, SHR-A1921, SHR-A2102) combined with adebrelimab to see if they help people with HER2-negative advanced breast cancer who have already tried other drugs.

  Recruiting Phase 2 Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06433609

• Combining HRS-4642 and Adebelimab for Advanced Pancreatic Cancer Treatment

  This study is testing a new combination of two drugs, HRS-4642 and adebelimab, to see if they can help people with advanced pancreatic cancer who haven't responded to other treatments.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT06427239

• Combination treatment for HER2-negative breast cancer brain metastasis

  This study is testing a new combination treatment for patients with HER2-negative breast cancer that has spread to the brain to see if it can help shrink tumors and improve survival.

  Recruiting Phase 2 Beijing 302 Hospital · Beijing, Beijing Municipality · NCT06418594

• Combining paclitaxel, apatinib, and adebrelimab for advanced gastric cancer treatment

  This study is testing a new combination of three drugs to see if it can help people with advanced stomach cancer who haven't had much success with other treatments.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Fuzhou, Fujian · NCT06415669

• Combining Adebrelimab with Chemotherapy and Radiation for Advanced Nasopharyngeal Cancer

  This study is testing if adding a new drug called Adebrelimab to standard chemotherapy and radiation can help people with advanced nasopharyngeal cancer feel better and improve their chances of recovery.

  Recruiting at 4 sites Phase 2 Sun Yat-sen University · Xiamen, Fujian and 3 other locations · NCT06349889

• Neoadjuvant treatment for HR Positive/HER2 Low Breast Cancer using SHR-A1811 and Adebrelimab

  This study is testing a new treatment combination for people with Stage II-III HR Positive/HER2 Low Breast Cancer to see if it can help shrink tumors before surgery.

  Recruiting Phase 2 Shengjing Hospital · Shenyang, Liaoning · NCT06340230

• Combination immunotherapy for advanced esophageal cancer

  This study is testing a new combination of treatments for patients with advanced esophageal cancer who haven't responded to previous therapies to see if it can help them.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06339619

• Combined therapy for advanced intrahepatic cholangiocarcinoma

  This study is testing a new combination of chemotherapy and targeted therapy to see if it can help people with advanced bile duct cancer feel better and live longer.

  Recruiting Phase 2 Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT06298968

• Treatment for resectable intrahepatic cholangiocarcinoma using a combination of drugs and chemotherapy

  This study is testing a new combination of drugs and chemotherapy to see if it can help people with resectable intrahepatic cholangiocarcinoma live longer and prevent the cancer from coming back after surgery.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06296563

• Combining chemotherapy and immunotherapy for advanced colorectal cancer treatment

  This study is testing a new combination of chemotherapy and immunotherapy to see if it helps people with advanced colorectal cancer live longer and feel better.

  Recruiting Phase 2 The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Jinhua, Zhejiang · NCT06282445

• Chemotherapy with Adebrelimab and Apatinib for Biliary Tract Cancer Treatment

  This study is testing a new combination of chemotherapy and two drugs, Adebrelimab and Apatinib, to see if it can help patients with a specific type of bile duct cancer who are at high risk of their cancer coming back after surgery.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, China/Guangdong · NCT06280508

• Combining Adebrelimab and TP Regimen for Treating Advanced Oral Cancer

  This study is testing if combining a new drug called Adebrelimab with a standard treatment can help people with advanced oral cancer before they have surgery.

  Recruiting Phase 2 Hospital of Stomatology, Wuhan University · Hubei, Wuhan · NCT06277791

• Combining short radiation with immunotherapy and chemotherapy for rectal cancer treatment

  This study is testing a new treatment for patients with a specific type of rectal cancer that combines short radiation, immunotherapy, and chemotherapy to see if it can help keep their organs and reduce the need for surgery.

  Recruiting Phase 2 Sir Run Run Shaw Hospital · Hangzhou, Zhejiang · NCT06266832

• Combining radiotherapy and immunotherapy for liver cancer with lymph node metastasis

  This study is testing a new treatment that combines radiation therapy with two medications to see if it helps people with liver cancer that has spread to lymph nodes feel better and have better results than current treatments.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06261125

• Short-course radiotherapy with Fruquintinib and Adebrelimab for advanced rectal cancer

  This study is testing a new treatment plan that combines short radiation therapy with Fruquintinib and Adebrelimab for people with advanced rectal cancer to see if it helps them better than current methods.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan · NCT06234007

• Neoadjuvant therapy for resectable intrahepatic cholangiocarcinoma

  This study is testing a new combination of chemotherapy and targeted therapy to see if it helps people with a specific type of liver cancer avoid recurrence after surgery.

  Recruiting at 3 sites Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu and 2 other locations · NCT06208462

• Combining adebrelimab with apatinib, gemcitabine, and cisplatin for treating biliary tract cancers

  This study is testing a new combination of medications to see if it can help people with high-risk biliary tract cancers do better before surgery.

  Recruiting Phase 1 First Affiliated Hospital of Fujian Medical University · Fuzhou, Fujian · NCT06181032

• Combining stereotactic radiotherapy with immunotherapy and chemotherapy for treating triple-negative breast cancer

  This study is testing if combining a new treatment with radiation and chemotherapy can help women with triple-negative breast cancer do better than just chemotherapy alone.

  Recruiting Phase 2 Shengjing Hospital · Shenyang, Liaoning · NCT06165900

• Combination treatment for advanced HR+/HER2- breast cancer

  This study is testing a new combination of treatments for people with advanced HR+/HER2- breast cancer to see if it can help them feel better after their previous treatments didn't work.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT06149130

• Combination therapy for neuroendocrine bladder carcinoma before surgery

  This study is testing a new combination treatment for people with neuroendocrine bladder cancer to see if it helps shrink the tumor before surgery.

  Recruiting at 5 sites Phase 2 RenJi Hospital · Nanjing, Jiangsu and 4 other locations · NCT06091124

• Treatment for advanced liver cancer using TACE with new medications

  This study is testing a new treatment combining TACE with two medications to see if it helps people with advanced liver cancer who can't have surgery.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT05970666

• Combining adebrelimab and fuzuloparib for treating recurrent platinum-resistant ovarian cancer

  This study is testing a new combination treatment of adebrelimab and fuzuloparib to see if it helps people with recurrent platinum-resistant ovarian cancer who haven't had other systemic treatments.

  Recruiting Phase 2 Fujian Cancer Hospital · Fujian · NCT05753826

Quick answers

How many clinical trials of Adebrelimab are recruiting right now?

90, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 66, Phase 1/2: 8, Phase 3: 6, Phase 2/3: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →